Results 31 to 40 of about 74,631 (338)
ADMET and DMPK, 2022 Levodopa is routinely co-administered with carbidopa in the management of Parkinson’s disease. Although the aforementioned combination therapy is effective, there may be fluctuating plasma levels of levodopa after oral administration.
Emelia Priscilla Imbeah +8 more
doaj +1 more source
Levodopa-induced pseudopheochromocytoma
European Journal of Case Reports in Internal Medicine, 2023 Pseudopheochromocytoma is a pathological condition presenting with paroxysmal hypertension with normal or moderate elevation in catecholamines and metanephrine levels, but no evidence of a tumoural cause. Imaging studies and I-123 metaiodobenzylguanidine scintigraphy are essential for exclusion of pheocromocytoma.
Joana Bernardino Cardoso +6 more
openaire +3 more sources
Impact of initial treatment on future symptoms and quality of life in Parkinson's disease
Chinese Journal of Contemporary Neurology and Neurosurgery, 2022 Objective To explore the effects of different initial drug treatment on motor symptoms, cognitive function and quality of life in patients with Parkinson's disease (PD).
LI Yu⁃wang +5 more
doaj +1 more source
Structural MRI Correlates of Episodic Memory Processes in Parkinson's Disease Without Mild Cognitive Impairment. [PDF]
, 2015 BackgroundChanges in episodic memory are common early in Parkinson's disease (PD) and may be a risk factor for future cognitive decline. Although medial temporal lobe (MTL) memory and frontostriatal (FS) executive systems are thought to play different ...
Filoteo, J Vincent +3 more
core +2 more sources
Neurobiology of Disease, 2016 Ras homolog enriched in striatum (Rhes) is a small GTP-binding protein that modulates signal transduction at dopamine receptors, and also activates mammalian target of rapamycin complex 1 (mTORC1). Rhes binding to mTORC1 is hypothesized to play a role in
Alberto Brugnoli +3 more
doaj +1 more source
Catecholamine-Based Treatment in AD Patients: Expectations and Delusions. [PDF]
, 2015 In Alzheimer disease, the gap between excellence of diagnostics and efficacy of therapy is wide. Despite sophisticated imaging and biochemical markers, the efficacy of available therapeutic options is limited.
Alessandro eStefani +9 more
core +3 more sources
Frontiers in Neurology, 2023 BackgroundThis study aimed to determine real-world prescribing patterns and determinants for Japanese patients with Parkinson's disease (PD), with a focus on patients ≥75 years.MethodsThis was a retrospective, observational, longitudinal study of ...
Morinobu Seki +4 more
doaj +1 more source
Incidence of mild cognitive impairment and dementia in Parkinson's disease: The Parkinson's disease cognitive impairment study [PDF]
, 2019 Background: Cognitive impairment in Parkinson's disease (PD) includes a spectrum varying from Mild Cognitive Impairment (PD-MCI) to PD Dementia (PDD). The main aim of the present study is to evaluate the incidence of PD-MCI, its rate of progression to ...
Baschi R. +9 more
core +1 more source
Levodopa versus non-levodopa brain language fMRI in Parkinson’s disease [PDF]
Einstein (São Paulo), 2012 Objective: To identify the effect of levodopa in language areas inParkinson’s disease patients. Methods: We evaluated 50 patientswith mild to moderate Parkinson’s disease, age and gender pairedto 47 healthy volunteers.
Paula Ricci Arantes +7 more
doaj
NOTCH2NLC Repeat Expansions in Parkinsonian Disorders: Clinical and Neuroimaging Characteristics
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Objective Neuronal intranuclear inclusion disease (NIID) is a neurodegenerative disorder caused by NOTCH2NLC GGC repeat expansions, with heterogeneous clinical manifestations, including parkinsonism. Recent studies have identified NOTCH2NLC repeat expansions in patients with Parkinson's disease (PD) and atypical parkinsonism (aPM), suggesting ...
Han‐Lin Chiang +7 more
wiley +1 more source